Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 9;6(11):7754-7760.
doi: 10.1021/acsomega.1c00157. eCollection 2021 Mar 23.

Ethyl Pyruvate as a Potential Defense Intervention against Cytokine Storm in COVID-19?

Omprakash Tanwar  1 , Aastha Soni  1 , Pawan Prajapat  1 , Tanu Shivhare  1 , Pooja Pandey  1 , Puneet Kumar Samaiya  1 , Sharad Prakash Pandey  1 , Parimal Kar  2
Affiliations

Ethyl Pyruvate as a Potential Defense Intervention against Cytokine Storm in COVID-19?

Omprakash Tanwar et al. ACS Omega. .

Abstract

COVID-19 is a deadly pandemic and has resulted in a huge loss of money and life in the past few months. It is well known that the SARS-CoV-2 gene mutates relatively slowly as compared to other viruses but still may create hurdles in developing vaccines. Therefore, there is a need to develop alternative routes for its management and treatment of COVID-19. Based on the severity of viral infection in COVID-19 patients, critically ill patients (∼5%, with old age, and comorbidities) are at high risk of morbidities. The reason for this severity in such patients is attributed to "misleading cytokine storm", which produces ARDS and results in the deaths of critically ill patients. In this connection, ethyl pyruvate (EP) controls these cytokines/chemokines, is an anti-inflammatory agent, and possesses a protective effect on the lungs, brain, heart, and mitochondria against various injuries. Considering these facts, we propose that the site-selective EP formulations (especially aerosols) could be the ultimate adjuvant therapy for the regulation of misleading cytokine storm in severely affected COVID-19 patients and could reduce the mortalities.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Immunopathological events (“cytokine storm”) of SARS-COV-2 infection and probable role of EP in ARDS management.
Figure 2
Figure 2
Structure and the CAS registry number of EP.
Figure 3
Figure 3
Different mechanisms of EP.
Figure 4
Figure 4
Various uses of EP.
See this image and copyright information in PMC

References

    1. WHO Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed 30 August 2020).
    1. WHO WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ (accessed 01 February 2021).
    1. Baric R. S. Emergence of a Highly Fit SARS-CoV-2 Variant. N. Engl. J. Med. 2020, 383, 2684–2686. 10.1056/nejmcibr2032888. - DOI - PubMed
    1. Callaway E.The coronavirus is mutating — does it matter? https://www.nature.com/articles/d41586-020-02544-6 (accessed 02 February 2021). - PubMed
    1. Soy M.; Keser G.; Atagündüz P.; Tabak F.; Atagündüz I.; Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Front. Immunol. 2020, 39, 2085–2094. 10.1007/s10067-020-05190-5. - DOI - PMC - PubMed